Cargando…

N-of-1 Trials in Cancer Drug Development

The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. In that regard, N-of-1 studies emerge as a potential addition to the drug development arsenal, although there are seve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gouda, Mohamed A., Buschhorn, Lars, Schneeweiss, Andreas, Wahida, Adam, Subbiah, Vivek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236153/ https://www.ncbi.nlm.nih.gov/pubmed/37070849 http://dx.doi.org/10.1158/2159-8290.CD-22-1377

Ejemplares similares

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Sodium fluoride (Na(18)F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors
por: Kairemo, K., et al.
Publicado: (2023)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
por: Desai, Aakash, et al.
Publicado: (2021)

Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development
por: Fermini, Bernard, et al.
Publicado: (2018)

A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens
por: Mutalik, Vivek K., et al.
Publicado: (2022)

End Points, Collection, Processing, and Time: Four Key Elements to Consider When Planning for Use of Handheld Devices in a Drug Development Setting
por: Pradhan, Vivek, et al.
Publicado: (2020)

A Historical Misconception in Clinical Trials of Drugs for Cancer—Age Grouping
por: Chen, Jingyu, et al.
Publicado: (2022)

Addressing Drug Resistance in Cancer: A Team Medicine Approach
por: Kulkarni, Prakash, et al.
Publicado: (2022)

Molecular interaction networks and drug development: Novel approach to drug target identification and drug repositioning
por: Loscalzo, Joseph
Publicado: (2022)

Is Open Science the Future of Drug Development?
por: Shaw, Daniel L.
Publicado: (2017)

Perspective on model‐informed drug development
por: Lesko, Lawrence J.
Publicado: (2021)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

Lights and Shadows in Immuno-Oncology Drug Development
por: Bergamino Sirvén, Milana, et al.
Publicado: (2021)

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Modeling and Simulation at the Interface of Nonclinical and Early Clinical Drug Development
por: Visser, S A G, et al.
Publicado: (2013)

Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development
por: Subramaniam, Sriram, et al.
Publicado: (2023)

Integrative Approaches in Pediatric Palliative Care
por: Shafto, Kate, et al.
Publicado: (2018)

Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018)

Drug discovery and development: Role of basic biological research
por: Mohs, Richard C., et al.
Publicado: (2017)

Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
por: Shakhnovich, Valentina, et al.
Publicado: (2019)

The economics of moonshots: Value in rare disease drug development
por: Yates, Nathan, et al.
Publicado: (2022)

A zebrafish-centric approach to antiepileptic drug development
por: Baraban, Scott C.
Publicado: (2021)

Model Informed Drug Development: Collaboration Through A Common Framework
por: Anziano, Richard J., et al.
Publicado: (2020)

Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience
por: Villalona-Calero, Miguel A., et al.
Publicado: (2023)

A proposal: a comprehensive platform to characterize tumors in Chinese and improve success in cancer drug discovery and development
por: Huang, Pearl S., et al.
Publicado: (2011)

Patients not patents: Drug research and development as a public enterprise
por: Gøtzsche, Peter C.
Publicado: (2018)

Model Informed Drug Development and Regulation in China: Challenges and Opportunities
por: Li, Li, et al.
Publicado: (2019)

Potential of kynurenine metabolites in drug development against neurodegenerative diseases
por: Kubicova, Lenka, et al.
Publicado: (2020)

Why 90% of clinical drug development fails and how to improve it?
por: Sun, Duxin, et al.
Publicado: (2022)

Has the Time Come for Predictive Computer Modeling in CNS Drug Discovery and Development?
por: Geerts, H, et al.
Publicado: (2012)

Regulatory developments in the conduct of clinical trials in India
por: Roy Chaudhury, R., et al.
Publicado: (2016)

Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model-Based Drug Development
por: Harnisch, L, et al.
Publicado: (2013)

Rare Mutations in Cancer Drug Resistance and Implications for Therapy
por: Beckman, Robert A., et al.
Publicado: (2020)

Advances in quantitative methods and modeling for complex generic drugs and opportunities to hybridize learnings between innovator and generic drug developers
por: Jayachandran, Priya
Publicado: (2023)

The Challenge of Interpreting Alanine Aminotransferase Elevations in Clinical Trials of New Drug Candidates
por: Church, Rachel J., et al.
Publicado: (2020)

Transcriptomic profiling does not refine mastocytosis diagnosis
por: Buschhorn, Lars, et al.
Publicado: (2023)

Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications
por: Husain, Aliabbas A., et al.
Publicado: (2021)

Application of Bayesian approaches in drug development: starting a virtuous cycle
por: Ruberg, Stephen J., et al.
Publicado: (2023)

Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
por: Rabinovici, Gil D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qnue9vrjrraq1ieinngcbu0tgk